Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,461 to 4,480 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Video Laryngoscope Group vs Direct Laryngoscope Group: deaths from any cause | 184 of 705 191 of 712 | -0.7 points -5.3 to 3.9 | 1,417 | NCT05239195 DirEct Versus VIdeo LaryngosCopE Trial |
| Video Laryngoscope Group vs Direct Laryngoscope Group: Esophageal Intubation | 6 of 705 9 of 712 | -0.4 points -1.6 to 0.7 | 1,417 | NCT05239195 DirEct Versus VIdeo LaryngosCopE Trial |
| AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants With Sustained Recovery | 617 of 710 594 of 707 | 2.9 points -0.8 to 6.6 | 1,417 | NCT05780437 AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
| AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants With a Safety Outcome Through Day 28 | 226 of 710 250 of 707 | -3.5 points -8.4 to 1.4 | 1,417 | NCT05780437 AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
| AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants Who Died From All Causes | 61 of 710 86 of 707 | -3.6 points -6.8 to -0.4 | 1,417 | NCT05780437 AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
| AZD7442 Plus SOC vs Placebo Plus SOC: deaths from any cause | 61 of 710 86 of 707 | -3.6 points -6.8 to -0.4 | 1,417 | NCT05780437 AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
| AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants With a Safety Outcome Through Day 90 | 179 of 710 214 of 707 | -5.1 points -9.7 to -0.4 | 1,417 | NCT05780437 AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
| AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants With a Safety Outcome Through Day 5 | 181 of 710 202 of 707 | -3.1 points -7.7 to 1.5 | 1,417 | NCT05780437 AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
| AZD7442 Plus SOC vs Placebo Plus SOC: serious adverse events | 36 of 710 39 of 707 | -0.4 points -2.8 to 1.9 | 1,417 | NCT05780437 AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
| ZD4054 vs Placebo: serious adverse events | 148 of 703 138 of 712 | 1.7 points -2.5 to 5.9 | 1,415 | NCT00626548 A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer |
| Distress Screening vs No Screening: Number of Patients With Oncology Visit | 728 of 730 683 of 683 | -0.3 points -1.0 to 0.3 | 1,413 | NCT02941614 Implementing Systematic Distress Screening in Breast Cancer |
| Distress Screening vs No Screening: Number of Participants Utilizing Behavioral Health Services | 287 of 730 247 of 683 | 3.2 points -1.9 to 8.2 | 1,413 | NCT02941614 Implementing Systematic Distress Screening in Breast Cancer |
| Distress Screening vs No Screening: Number of Patients With Primary Care Visit | 648 of 730 616 of 683 | -1.4 points -4.6 to 1.8 | 1,413 | NCT02941614 Implementing Systematic Distress Screening in Breast Cancer |
| Bundles vs Bundles and Discount: Number of Participants Who Kept Healthy Bundle Default Shopping Cart Items in Basket at Purchase | 679 of 727 655 of 686 | -2.1 points -4.5 to 0.3 | 1,413 | NCT04766034 Impact of Behavioral Economic Strategies on Low-Income Older Adults' Food Choices in Online Retail Settings |
| Influenza Virus Vaccine (Pooled) vs Comparator Influenza Vaccine: serious adverse events | 11 of 1,209 4 of 202 | -1.1 points -4.1 to 0.3 | 1,411 | NCT00617851 Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old |
| Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Tobacco Abstinence, Self-report | 276 of 706 218 of 703 | 8.1 points 3.1 to 13.0 | 1,409 | NCT03603496 Post-Discharge Smoking Cessation Strategies: Helping HAND 4 |
| Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Engagement in Cessation Treatment | 434 of 706 319 of 703 | 16.1 points 10.9 to 21.2 | 1,409 | NCT03603496 Post-Discharge Smoking Cessation Strategies: Helping HAND 4 |
| Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Tobacco Abstinence, Self-report | 234 of 706 202 of 703 | 4.4 points -0.4 to 9.2 | 1,409 | NCT03603496 Post-Discharge Smoking Cessation Strategies: Helping HAND 4 |
| Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Tobacco Abstinence, Self-report | 291 of 706 246 of 703 | 6.2 points 1.2 to 11.3 | 1,409 | NCT03603496 Post-Discharge Smoking Cessation Strategies: Helping HAND 4 |
| Transitional Tobacco Care Management (TTCM) vs eReferral to State Tobacco Quitline (QL): Engagement in Cessation Treatment | 489 of 706 369 of 703 | 16.8 points 11.7 to 21.7 | 1,409 | NCT03603496 Post-Discharge Smoking Cessation Strategies: Helping HAND 4 |
Code
curl "https://conductscience.org/api/comparisons/v1?page=224"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=224
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT05239195-deaths",
"title": "Video Laryngoscope Group vs Direct Laryngoscope Group: deaths from any cause",
"summary": "184 of 705 against 191 of 712; risk difference -0.7 points, 95% interval -5.3 to 3.9; NCT05239195, DirEct Versus VIdeo LaryngosCopE Trial",
"record": "/library/comparisons/NCT05239195-deaths",
"nct_id": "NCT05239195",
"kind": "deaths",
"participants": 1417,
"risk_difference": {
"value": -0.007265519164873724,
"lower": -0.05311381112068955,
"upper": 0.03864893916815562
},
"group_1": "184 of 705",
"group_2": "191 of 712",
"difference": "-0.7 points",
"interval": "-5.3 to 3.9",
"trial_title": "DirEct Versus VIdeo LaryngosCopE Trial"
},
{
"id": "NCT05239195-fffa50ba",
"title": "Video Laryngoscope Group vs Direct Laryngoscope Group: Esophageal Intubation",
"summary": "6 of 705 against 9 of 712; risk difference -0.4 points, 95% interval -1.6 to 0.7; NCT05239195, DirEct Versus VIdeo LaryngosCopE Trial",
"record": "/library/comparisons/NCT05239195-fffa50ba",
"nct_id": "NCT05239195",
"kind": "outcome",
"participants": 1417,
"risk_difference": {
"value": -0.004129811140329906,
"lower": -0.016245786697620463,
"upper": 0.0074612120071021835
},
"group_1": "6 of 705",
"group_2": "9 of 712",
"difference": "-0.4 points",
"interval": "-1.6 to 0.7",
"trial_title": "DirEct Versus VIdeo LaryngosCopE Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=225",
"request_id": "L09nI5nz03qgZMC1"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant